Sign in
VBIV Stock Price, Chart, Stats & News
VBI Vaccines Inc.
Save
1.87M
Market cap
–
Current P/E
–
Forward P/E
VBIV chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -66.98% |
Operating margin | -637.08% |
Pretax margin | -1069.29% |
Net margin | -1069.29% |
Effective tax rate | – |
ROA | -106.77% |
ROE | -258.99% |
D/E | 7.05x |
Interest coverage ratio | -6.86x |
VBIV valuation
P/E | – |
P/S | 0.22x |
P/B | 0.14x |
P/CF | -0.02x |
P/FCF | -0.03x |
P/OCF | -0.02x |
PEG | -0.00x |
EV multiple | 0.33x |
About
VBI Vaccines Inc. is a biopharmaceutical firm dedicated to the development and commercialization of vaccines, targeting both infectious diseases and immuno-oncology. Among its commercial offerings is Sci-B-Vac, a prophylactic vaccine designed to prevent hepatitis B (HBV). The company is also actively developing VBI-2601 (also identified as BRII-179), an investigational immunotherapeutic aimed at treating chronic hepatitis B infection.
Similar securities
Based on sector and market capitalization
Report issue